📊 IDYA Key Takeaways
Is IDEAYA Biosciences, Inc. (IDYA) a Good Investment?
IDEAYA is an early-stage pharmaceutical company with explosive revenue growth (3024% YoY) and a fortress balance sheet ($157.5M cash, zero debt) providing 2+ years of runway, but current fundamentals are deeply unprofitable with -$108.5M operating losses against minimal $6.6M revenue. Improving loss metrics YoY suggest progress, but path to profitability remains uncertain without visibility into pipeline success.
IDEAYA’s fundamentals show a step‑change in revenue but the business remains structurally loss‑making with negative free cash flow. A debt‑free, highly liquid balance sheet provides multi‑year runway to advance programs, while EPS loss has narrowed. However, profitability hinges on sustaining revenue (likely milestone/collaboration‑driven) and moderating R&D spend.
IDEAYA Biosciences, Inc. Key Strengths (IDYA)
- Exceptional revenue growth momentum of 3024% YoY indicating recent commercialization traction
- Fortress balance sheet with $1.0B assets, $157.5M cash, zero long-term debt eliminates near-term solvency risk
- Improving unit economics with 62% YoY reduction in diluted EPS losses demonstrates operational progress
- Excellent liquidity (10.74x current ratio) provides multi-year operational runway without external funding pressure
- Exceptional liquidity (current ratio 11.34x; quick 11.34x)
- Debt‑free balance sheet with low liabilities and $1.02B equity
- Explosive revenue growth and improved EPS loss trajectory
IDYA Stock Risks: IDEAYA Biosciences, Inc. Investment Risks
- Massive operating losses ($108.5M) against minimal revenue ($6.6M) reveal unsustainable cash burn model
- Catastrophic operating/net margins (-1654%/-1502%) reflect pre-commercial stage with heavy R&D and regulatory expenses
- Approximately 2 years of cash runway at $75M annual burn rate dependent on achieving profitability or capital raises
- Early-stage pharmaceutical company faces inherent high clinical and regulatory failure risk across pipeline
- Minimal insider activity (1 Form 4 filing in 90 days) suggests limited insider confidence or ownership
- Persistent operating losses (‑72.8% margin) and negative FCF (‑33.6% margin)
- Revenue quality/sustainability risk if milestone‑driven; gross margin N/A
- Ongoing cash burn may necessitate external financing if not offset by durable revenue
Key Metrics to Watch
- Revenue growth sustainability and path to $50M+ quarterly revenue
- Operating cash burn trajectory and timeline to cash flow breakeven
- Clinical pipeline progression, regulatory milestones, and commercial partnership announcements
- Cash runway extension through partnerships, milestone payments, or equity capital raises
- Operating cash flow (TTM) / burn rate
- Deferred revenue and collaboration vs recurring revenue mix
IDEAYA Biosciences, Inc. (IDYA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.74x current ratio provides a solid financial cushion.
IDYA Profit Margin, ROE & Profitability Analysis
IDYA vs Healthcare Sector: How IDEAYA Biosciences, Inc. Compares
How IDEAYA Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IDEAYA Biosciences, Inc. Stock Overvalued? IDYA Valuation Analysis 2026
Based on fundamental analysis, IDEAYA Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IDEAYA Biosciences, Inc. Balance Sheet: IDYA Debt, Cash & Liquidity
IDYA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: IDEAYA Biosciences, Inc.'s revenue has grown significantly by 683% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.96 indicates the company is currently unprofitable.
IDYA Revenue Growth, EPS Growth & YoY Performance
IDYA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.6M | -$72.2M | $-0.82 |
| Q3 2025 | $207.8M | -$30.4M | $-0.34 |
| Q3 2024 | N/A | -$27.4M | $-0.46 |
| Q2 2024 | N/A | -$27.9M | $-0.50 |
| Q1 2024 | N/A | -$23.6M | $-0.49 |
| Q3 2023 | $8.0M | $1.6M | $0.04 |
| Q2 2023 | $3.5M | -$22.1M | $-0.50 |
| Q1 2023 | $7.9M | -$14.0M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IDEAYA Biosciences, Inc. Dividends, Buybacks & Capital Allocation
IDYA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for IDEAYA Biosciences, Inc. (CIK: 0001676725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IDYA
What is the AI rating for IDYA?
IDEAYA Biosciences, Inc. (IDYA) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 54% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IDYA's key strengths?
Claude: Exceptional revenue growth momentum of 3024% YoY indicating recent commercialization traction. Fortress balance sheet with $1.0B assets, $157.5M cash, zero long-term debt eliminates near-term solvency risk. ChatGPT: Exceptional liquidity (current ratio 11.34x; quick 11.34x). Debt‑free balance sheet with low liabilities and $1.02B equity.
What are the risks of investing in IDYA?
Claude: Massive operating losses ($108.5M) against minimal revenue ($6.6M) reveal unsustainable cash burn model. Catastrophic operating/net margins (-1654%/-1502%) reflect pre-commercial stage with heavy R&D and regulatory expenses. ChatGPT: Persistent operating losses (‑72.8% margin) and negative FCF (‑33.6% margin). Revenue quality/sustainability risk if milestone‑driven; gross margin N/A.
What is IDYA's revenue and growth?
IDEAYA Biosciences, Inc. reported revenue of $6.6M.
Does IDYA pay dividends?
IDEAYA Biosciences, Inc. does not currently pay dividends.
Where can I find IDYA SEC filings?
Official SEC filings for IDEAYA Biosciences, Inc. (CIK: 0001676725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IDYA's EPS?
IDEAYA Biosciences, Inc. has a diluted EPS of $-1.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IDYA's fundamental grade?
Based on our AI fundamental analysis in May 2026, IDEAYA Biosciences, Inc. has a B grade with 54% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IDYA stock overvalued or undervalued?
Valuation metrics for IDYA: ROE of -10.5% (sector avg: 15%), net margin of -1,502.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IDYA's AI grade for 2026?
Our dual AI analysis gives IDEAYA Biosciences, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IDYA's free cash flow?
IDEAYA Biosciences, Inc.'s operating cash flow is $-75.2M, with capital expenditures of $967.0K. FCF margin is -1,160.6%.
How does IDYA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,502.1% (avg: 12%), ROE -10.5% (avg: 15%), current ratio 10.74 (avg: 2).